递表 | 创新型抗菌肽治疗药物公司「普莱医药-B」递表港交所，核心产品进入临床2期

Core Viewpoint - The company, Plai Pharmaceuticals-B, is a leading innovative antimicrobial peptide (AMP) therapeutics company that has submitted its IPO application to the Hong Kong Stock Exchange, aiming to raise funds for its clinical development pipeline and expand its market presence [1][2]. Company Overview - Plai Pharmaceuticals-B was established in April 2009 and focuses on four core therapeutic areas: anti-infection, metabolic diseases, oncology, and autoimmune diseases [1]. - The company has nine candidate drugs in its pipeline, including one core product (PL-5) and two major products (PL-3301 and PL-18) targeting various serious health conditions [1][2]. Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenues of approximately RMB 0.05 billion, with a net loss of RMB 1.58 billion [6]. - In the first nine months of 2025, revenues were approximately RMB 0.03 billion, reflecting a year-on-year decline of 34.12% [6]. - The gross profit margin for 2024 was approximately 41.86%, while the net profit margin was -3,048.46% [6]. Product Pipeline - The core product PL-5 is the first of its kind in the global market to submit a New Drug Application (NDA) and is currently undergoing Phase II clinical trials in the U.S. [2]. - PL-3301 and PL-18 are in clinical development for treating oropharyngeal candidiasis and vulvovaginal candidiasis, respectively [2]. - The company is also developing PL-AC-2001, a potential PARP-1 degrader for oncology, utilizing proprietary PROTAC technology [4]. Industry Overview - The global peptide therapeutics market is projected to grow from USD 62.8 billion in 2020 to USD 109.6 billion by 2024, with a compound annual growth rate (CAGR) of 5.8% expected from 2030 to 2035 [8]. - The Chinese peptide therapeutics market is expected to reach USD 40.7 billion by 2035, growing at a CAGR of 13.7% during the same period [8]. Comparable Companies - Comparable companies in the industry include AbbVie and Tansheng Bo Pharmaceutical-B, with AbbVie having a current market capitalization of approximately USD 409.15 billion and a recent fiscal year revenue of USD 61.16 billion [15].